Tumor regression by adenovirus expression of wild-type p53
US6143290A · kind A · utility
53Cited by
4References
94Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 7, 1994 |
| Grant date | Nov 7, 2000 |
| Priority date | — |
| Expiry date | Apr 7, 2014 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/10343
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described are simplified and efficient methods for preparing recombinant adenovirus using liposome-mediated cotransfection and the direct observation of a cytopathic effect (CPE) in the transfected cells. Also disclosed are compositions and methods involving novel p53 adenovirus constructs, including methods for restoring p53 function and tumor suppression in cells and animals having abnormal p53.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.